About MAP Pharmaceuticals (NASDAQ:MAPP)
MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions
What is MAP Pharmaceuticals' stock symbol?
MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP."
Who are some of MAP Pharmaceuticals' key competitors?
Some companies that are related to MAP Pharmaceuticals include Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Novartis (NVS), Pfizer (PFE), Roche (ROG), AbbVie (ABBV), Merck & Co., Inc. (MRK), Amgen (AMGN), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), Bayer (BAYN), Sanofi (SAN), Celgene (CELG) and CSL (CSL).
How do I buy MAP Pharmaceuticals stock?
Shares of MAP Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact MAP Pharmaceuticals?
MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581.
MarketBeat Community Rating for MAP Pharmaceuticals (MAPP)MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
MAP Pharmaceuticals (NASDAQ:MAPP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
MAP Pharmaceuticals (NASDAQ:MAPP) Earnings History and Estimates Chart
MAP Pharmaceuticals (NASDAQ MAPP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
MAP Pharmaceuticals (NASDAQ:MAPP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for MAP Pharmaceuticals (NASDAQ:MAPP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for MAP Pharmaceuticals (NASDAQ MAPP)
No insider trades for this company have been tracked by MarketBeat.com
MAP Pharmaceuticals (NASDAQ MAPP) News Headlines
No headlines for this company have been tracked by MarketBeat.com
MAP Pharmaceuticals (NASDAQ:MAPP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MAP Pharmaceuticals (NASDAQ:MAPP) Income Statement, Balance Sheet and Cash Flow Statement
MAP Pharmaceuticals (NASDAQ MAPP) Stock Chart for Tuesday, February, 20, 2018